Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carles Pericay

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Medicina Clinica|October 31, 2002
[Description of a new TP53 gene germline mutation in a family with the Li-Fraumeni syndrome. Genetic counselling to healthy mutation carriers]Judith Balmaña, Josep Nomdedéu, Orland Díez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 24, 2024
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)Carles Pericay, Clara Montagut, Juan José Reina, et al.
Diseases of the Colon and Rectum|December 14, 2020
Completion Surgery in Unfavorable Rectal Cancer after Transanal Endoscopic Microsurgery: Does It Achieve Satisfactory Sphincter Preservation, Quality of Total Mesorectal Excision Specimen, and Long-term Oncological Outcomes?Xavier Serra-Aracil, Ana Galvez Saldaña, Laura Laura Mora-Lopez, et al.
BMC Cancer|August 12, 2023
Treatment with anticancer drugs for advanced pancreatic cancer: a systematic reviewJosefina Salazar, Javier Bracchiglione, Olga Savall-Esteve, et al.
Clinical Colorectal Cancer|June 9, 2020
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert OpinionAna Fernández-Montes, Cristina Grávalos, Carles Pericay, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 25, 2010
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximabXabier Garcia-Albeniz, Carles Pericay, Virginia Alonso-Espinaco, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Teleoncology: A Solution for Everyone? A Single-Center Experience with Telemedicine during the Coronavirus Disease 2019 (COVID-19) PandemicPaula Ribera, Sandra Soriano, Carla Climent, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 6, 2006
Gastrointestinal stromal tumors: experience in 49 patientsEva Artigau Nieto, Alexis Luna Aufroy, Elsa Dalmau Pórtulas, et al.
Medical Oncology (Northwood, London, England)|January 23, 2013
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancerJordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, et al.
Clinical Breast Cancer|May 19, 2007
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 statusLuis A Fernández-Morales, Miquel A Seguí, Xavier Andreu, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Medicina Clinica|October 31, 2002
[Description of a new TP53 gene germline mutation in a family with the Li-Fraumeni syndrome. Genetic counselling to healthy mutation carriers]Judith Balmaña, Josep Nomdedéu, Orland Díez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 24, 2024
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)Carles Pericay, Clara Montagut, Juan José Reina, et al.
Diseases of the Colon and Rectum|December 14, 2020
Completion Surgery in Unfavorable Rectal Cancer after Transanal Endoscopic Microsurgery: Does It Achieve Satisfactory Sphincter Preservation, Quality of Total Mesorectal Excision Specimen, and Long-term Oncological Outcomes?Xavier Serra-Aracil, Ana Galvez Saldaña, Laura Laura Mora-Lopez, et al.
BMC Cancer|August 12, 2023
Treatment with anticancer drugs for advanced pancreatic cancer: a systematic reviewJosefina Salazar, Javier Bracchiglione, Olga Savall-Esteve, et al.
Clinical Colorectal Cancer|June 9, 2020
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert OpinionAna Fernández-Montes, Cristina Grávalos, Carles Pericay, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 25, 2010
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximabXabier Garcia-Albeniz, Carles Pericay, Virginia Alonso-Espinaco, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Teleoncology: A Solution for Everyone? A Single-Center Experience with Telemedicine during the Coronavirus Disease 2019 (COVID-19) PandemicPaula Ribera, Sandra Soriano, Carla Climent, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 6, 2006
Gastrointestinal stromal tumors: experience in 49 patientsEva Artigau Nieto, Alexis Luna Aufroy, Elsa Dalmau Pórtulas, et al.
Medical Oncology (Northwood, London, England)|January 23, 2013
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancerJordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, et al.
Clinical Breast Cancer|May 19, 2007
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 statusLuis A Fernández-Morales, Miquel A Seguí, Xavier Andreu, et al.
Pageof 7